Core Insights - IN8bio, Inc. announced promising clinical data for INB-100, an allogeneic gamma-delta T cell therapy for complex leukemias, particularly AML, showing potential for durable long-term remissions and improved survival [1][3][4] Clinical Trial Results - INB-100 demonstrated a 100% complete remission (CR) rate in AML patients across both original and expansion cohorts, with a median follow-up of 20.1 months [4][5] - The original cohort of AML patients achieved a median CR duration of 23.3 months, with some patients remaining in remission for over three years [5] - One-year progression-free survival (PFS) and overall survival (OS) rates for all patients treated with INB-100 were 90.9% and 100%, respectively, while AML patients had 100% PFS and OS at one year [5] Comparison with Historical Data - Historical controls showed a PFS of 67.8% and OS of 74.7% at one year from CIBMTR, and a PFS of 57.4% and OS of 66.7% at one year from KUCC, indicating INB-100's superior outcomes [5] Patient Demographics and Tolerability - The trial included older, high-risk patients (median age = 68) who had complex diseases or had failed multiple prior therapies, yet they achieved durable remissions with manageable side effects [5][6] - INB-100 therapy was well-tolerated, with no significant cytokine release syndrome (CRS) or neurotoxicity reported, and manageable graft-versus-host disease (GvHD) [5][6] Future Outlook - The company is committed to expanding the trial network and preparing for a potential registrational trial, aiming to provide broader patient access to INB-100 [6][9]
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients